Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02

Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma

(2012) M. A. Davies et al.   CLINICAL CANCER RESEARCH

Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme

(2010) John D. Hainsworth et al.   CANCER

Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks

(2010) J. N. Sarkaria et al.   CLINICAL CANCER RESEARCH

Sorafenib exerts anti-glioma activity in vitro and in vivo

(2010) Markus D. Siegelin et al.   NEUROSCIENCE LETTERS

Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancer

(2009) Isamu Okamoto et al.   INVESTIGATIONAL NEW DRUGS

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

Malignant Gliomas in Adults

(2008) Patrick Y. Wen et al.   NEW ENGLAND JOURNAL OF MEDICINE